The Swiss pharma company Novartis ranks in the top 10 of pharma companies, and boasts drugs ranging from Ritalin and Lamisil to clozapine, Diovan and Gilenya. It also owns the generic giant Sandoz. Unlike its competitor, GlaxoSmithKline, Novartis did not offer free flu vaccines during the H1N1 flu epidemic.

In March 2011, Novartis gained FDA approval for Gilenya, its multiple sclerosis drug. The nod came on the heels of a narrower EMA approval, which grants second-line treatment status. According to experts, the drug could be worth $3 billion in annual sales as the first oral MS drug on the market.

Novartis purchased the remaining portion of eye care company Alcon in a $12.9 billion deal at the end of 2010, marking the end of one of the biggest battles in biopharma. Although many analysts predicted heavy layoffs in 2010 from the company, only 1,400 jobs were cut in December 2010, with the disclaimer that more could be on the way as Novartis, like others in the industry, analyzes its efficiency.

Tag:

Novartis

Latest Headlines

Latest Headlines

Pfizer beats out Novartis with FDA MenB nod

We have a winner. In a two-horse race to grab the first-ever U.S. approval for a meningitis B vaccine, Pfizer has emerged victorious, nabbing the FDA's blessing Wednesday.

For Novartis' respiratory ambitions, it's a tale of 'two worlds'

Targeting different markets naturally requires using different marketing strategies. But for Novartis, which is aiming to become a major respiratory player, its approaches within and outside the U.S. could end up being worlds apart.

Australia's CSL gets three Novartis vaccine plants in $275M deal

For $275 million, Australia's CSL is buying from Novartis a network of vaccine manufacturing facilities, as well as a portfolio of products.

Novartis officially bows out of vaccines with flu sale to CSL

Novartis' 8-year foray into vaccines is officially coming to a close. After divesting the bulk of its unit to GlaxoSmithKline in an April deal, the pharma giant Sunday announced it had agreed to sell its flu shot business to Australia's CSL. And with that, it'll make its exit from a field that's given it trouble since its Chiron buyout in 2006.

Novartis drafts TV celeb Nick Cannon to talk up importance of flu vaccines

To help show Americans just how important its flu vaccines are, Novartis has teamed up with entertainer Nick Cannon, who's advising consumers to prepare for flu season by getting their shots and stocking up on the Swiss pharma's over-the-counter remedy, Theraflu.

Novartis recruits Nick Cannon for double-whammy flu campaign

In choosing a face for its new Theraflu Fluprint campaign, Novartis Consumer Health was on the hunt for someone who understood the importance of being flu-ready--and who used Theraflu products, of course, company spokeswoman Liz Power told FiercePharmaMarketing.

BARDA calls on Novartis, GSK, Emergent to pitch in with Ebola drug

The U.S. government invested $440 million in three vaccine plants in the U.S. in 2012 with the proviso that if something like a pandemic occurred, it could call on them to produce drugs that it required. With Ebola spreading, those calls have now been made.

Bexsero could be cost-effective for England, model says--but not at Novartis' price

What's the value of Novartis' meningitis B vaccine, Bexsero, to the U.K.? It's a question the company and the country's government have been debating for months now, unable to come to terms on a reasonable price for the jab. But medical journal The BMJ might have an answer.

Novartis breaks out in song with MS campaign featuring David Osmond

Novartis has added a bit of pop to its already extensive Gilenya marketing. Not content with a Twitter feed, a YouTube channel, a self-management smartphone app, and a gaggle of awareness pushes, the Swiss drugmaker is now in the music business.

Drug delivery: Fertile ground for pharma-device company partnerships?

BOSTON-- Whether through collaboration with academia or buyouts of smaller players, panelists at the Partnership Opportunities in Drug Delivery conference concurred that Big Pharma is increasingly looking externally for innovation and using its size and financial to power candidates through clinicial and onto the market.